Neurology, MS & Neuroimmunology
-
-
Administers Grant
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and
Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
-
A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
-
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
-
A Phase II, multicenter, randomized, double-blind, parallel gruop, placebo-controlled, adaptive dose-ranging study to eveluate the efficacy and safety of AIN457 (Secuinumab) (IV) inn patients with relapsing mutiple sclerosis.
-
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica
-
A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in
patients with relapsing forms of multiple sclerosis (PASS)
-
An open-label phase IV study to evaluate whether a Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera® in MS
-
BEAT-MS
-
BEAT-MS
-
Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE)
-
ECHO MS 2020
-
PA Fellowship in Clinical Neuroimmunology